Clinical Study of NovoClasp for Treating Moderate to Severe and Severe Degenerative Mitral Regurgitation

Degenerative Mitral Valve Disease Clinical Trial

Official title:

A Prospective, Multicenter, Single-arm Clinical Study of NovoClasp Transcatheter Mitral Valve Clip and Steerable Guide Catheter for Treating Moderate to Severe and Severe Degenerative Mitral Regurgitation (DMR)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06021509
• Other study ID #: YM-2022-001
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 15, 2022
• Est. completion date: June 25, 2028

Study information

• Verified date: August 2023
• Source: Enlight Medical Technologies (Shanghai) Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To validate the safety and efficacy of transcatheter edge-to-edge repair (TEER) using the NovoClasp® transcatheter mitral valve clip and steerable guide catheter in the treatment of moderate to severe and severe degenerative mitral regurgitation (DMR).

Description:

This trial is a prospective multi-center single-arm confirmatory study. A total of 102 subjects will be enrolled in multiple centers nationwide. Subjects who meet the trial requirements, fulfill the inclusion criteria, voluntarily participate in the study, and provide informed consent will undergo mitral edge-to-edge repair using the NovoClasp® transcatheter mitral valve clip system and steerable guide catheter for the treatment of moderate to severe or severe degenerative mitral regurgitation (DMR). Follow-up assessments will be conducted at discharge, as well as at 30 days, 90 days, 180 days, and 360 days postoperatively. The primary endpoint will be the treatment effectiveness rate at 360 days post-surgery. Secondary endpoint measures include treatment effectiveness at other time points, surgical success rate, all-cause mortality, device/procedure-related mortality, incidence of adverse events, and serious adverse event rates. The trial aims to comprehensively assess the safety and efficacy of the NovoClasp® transcatheter mitral valve clip and steerable guide catheter produced by Enlight Medical Technologies (Shanghai) Co., Ltd..

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 102
• Est. completion date: June 25, 2028
• Est. primary completion date: June 25, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subjects must meet all of the following criteria to be eligible for this study.

1. Age 18 years.

2. Willingness to comply with the protocol requirements and data collection procedures, ability to understand the purpose of the trial, voluntary participation, and signing of informed consent by the subject or legal guardian.

3. Confirmation by echocardiography of moderate to severe (3+) or severe (4+) degenerative mitral regurgitation.

4. Echocardiography showing left ventricular ejection fraction 30%, left ventricular end-systolic diameter (LVESD) 60mm, and pulmonary artery systolic pressure (PASP) 70 mmHg.

5. NYHA functional classification II-IV.

6. Presence of a primary regurgitant jet; if a secondary regurgitant jet is present, it should be clinically insignificant based on investigator assessment.

7. Evaluated by a multidisciplinary team as suitable for the investigational procedure using the study device.

8. Society of Thoracic Surgeons (STS) score 4 or evaluated as high surgical risk for mitral valve repair by two cardiac surgeons.

Exclusion Criteria:

Subjects meeting any of the following criteria are not eligible for this study.

1. History of prior mitral valve surgery or heart transplant.

2. Severe organ dysfunction that may affect study evaluation, including but not limited to:

1. Right heart failure or biventricular heart failure.

2. Severe restrictive or obstructive lung disease (COPD) requiring continuous oxygen therapy or oral steroid treatment.

3. Severe renal insufficiency requiring or likely to require continuous renal replacement therapy (CRRT) or dialysis postoperatively.

4. Severe carotid artery stenosis confirmed by imaging to be >70%.

3. History of cerebrovascular accident within the past 1 month.

4. Acute deep vein thrombosis or acute pulmonary embolism history.

5. Any known active infection.

6. Active infective endocarditis (eligible 6 weeks after standard antimicrobial treatment), rheumatic heart valve disease, or radiation-induced valve disease.

7. Cardiac or major vascular surgical or interventional procedure within 30 days (coronary angiography is allowed).

8. Coexisting moderate or greater valvular disease (aortic valve, tricuspid valve, pulmonary valve stenosis or regurgitation).

9. Known other cardiac or major vascular diseases requiring surgical or interventional intervention, including but not limited to coronary artery disease, myocardial disease, aortic disease (except for coronary angiography).

10. Echocardiographic evidence of intracardiac mass, thrombus, vegetation, or mitral valve orifice area (MVOA) 4.0 cm2, or any condition unsuitable for the study device, including but not limited to:

1. Unsuitable for leaflet capture due to severe calcification or cleft.

2. Lack of primary and secondary chordal support in the capture area.

3. Leaflet free edge length < 0.8 cm.

11. Known conditions that preclude study procedure (including but not limited to allergies to device components, coagulation disorders, life expectancy < 1 year).

12. Pregnant or breastfeeding women or those planning pregnancy during the trial period.

13. Intending or currently participating in another interventional clinical trial.

14. Other conditions deemed inappropriate for participation in this study by the investigator.

Related Conditions & MeSH terms

• Degenerative Mitral Valve Disease
• Mitral Valve Insufficiency

Intervention

Device:
• NovoClasp® transcatheter mitral valve clip and steerable guide catheter
The experimental device is a class III implanted valve device, which will be used to treat the mitral valve regurgitation via transcatheter edge-to-edge repair.

Locations

Country	Name	City	State
China	Beijing Anzhen Hospital, Capital Medical University	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Enlight Medical Technologies (Shanghai) Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	All cause mortality		through study completion, an average of 1 year
Other	Device/Procedure-related mortality		through study completion, an average of 1 year
Other	Major adverse events		through study completion, an average of 1 year
Other	Serious adverse events		through study completion, an average of 1 year
Other	Number of participants with device-related adverse events		through study completion, an average of 1 year
Primary	Treatment effectiveness rate	Treatment effectiveness is defined as the success of the procedure with the mitral valve regurgitation sustained at moderate or lower (<=2+) after the surgery, without major adverse events or secondary interventions (interventional or surgical).	1 year
Secondary	Procedural success rate	Successful implantation of a single device as intended by the operator, successful retrieval of the delivery system, absence of device migration, dislodgment, embolization, related complications, or other unforeseen incidents.	immediately after procedure
Secondary	Procedural success rate	Defined as successful completion of the investigational procedure as intended by the operator (implantation of at least 1 study device) and reduction of mitral valve regurgitation to moderate or below (<=2+), without open surgery, major adverse events during the perioperative period, or secondary interventions (interventional or surgical).; Note: Major adverse events include cardiovascular-related deaths, stroke, myocardial infarction, need for renal replacement therapy, severe bleeding (hemoglobin decrease >=3g/dL compared to baseline, or requiring >=3 units of blood transfusion), or organ damage, failure, or death dur to blood loss.	During the perioperative period
Secondary	Rate of Treatment success	Treatment effectiveness is defined as the success of the procedure with the mitral valve regurgitation sustained at moderate or lower (<=2+) after the surgery, without major adverse events or secondary interventions (interventional or surgical).	30 days, 180 days
Secondary	Changes in New York Heart Association (NYHA) Functional Classification	The NYHA Classification provides nomenclature to describe an overall cardiac appraisal of the status of a patient with heart disease.; Class I: Patients with cardiac disease but without resulting limitation of physical activity.; Class II: patients with cardiac disease resulting in slight limitation of physical activity.; Class III: Patients with cardiac disease resulting in marked limitation of physical activity.; Class IV: Patient with cardiac disease resulting in inability to carry on any physical activity without discomfor.	through study completiong, an average of 1 year.